Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
From past CEO blog
We have also brought on to our Scientific and Clinical Advisory Board the lead inventors of both programs, Dr. Kapil Bharti at NEI and Dr. Dimiter Dimitrov now at Pitt. Soon I hope to be able to announce the Principal Investigators for the Clinical trials for both. But none of the trials can start, and indeed their results can’t count without laying the foundation first in preparation for, and then properly manufacturing the drug. So indeed, this little candle we are burning at both ends rights now throws it’s light all the way from the bench to the bedside.
....the plot thickens.
Forgot about Dr. Dimitrov. Lots of irons in the fire--and any iron will be enough to see this thing ablaze. (pun intended).
Disclaimer: Added to CUBT at $0.048.
GLTA
Look at this from that Linked IN link.
Kapil Bharti
2nd degree connection 2nd
Senior Investigator at The National Institutes of Health
1w
Excited to work with Curative Biotech on evaluating metformin eye drops as a potential treatment for retinal degenerative diseases. This technology showed promising results in preclinical studies performed using patient stem cell derived eye cells. Two publications on the way.
3 Replies on Kapil Bharti’s comment
See profile for Rajarshi Pal, Ph.D.
Chief Scientist, Eyestem Research, Centre for Cellular and Molecular Platforms (C-CAMP), NCBS-TIFR Campus, Bangalore
1w
That’s amazing news! Metformin is a pleiotropic molecule and unsurprisingly there is evidence of its therapeutic potential in AMD patients, through retrospective trials. However knowing the mechanism would be exciting- perhaps through its role as a TGF-beta inhibitor!??
See profile for Kapil Bharti
Kapil Bharti
Senior Investigator at The National Institutes of Health
1w
Rajarshi Pal, Ph.D. Thanks Raj! As your said, it’s a pleiotropic molecule. We see effects on lipid metabolism, mitochondrial function, cell polarity, and EMT.
Rajarshi Pal, Ph.D.
Chief Scientist, Eyestem Research, Centre for Cellular and Molecular Platforms (C-CAMP), NCBS-TIFR Campus, Bangalore
6d
Kapil Bharti Wow, sounds very interesting! Earlier, we too had identified the role of metformin in type 1 and type 3 EMT using stem cell lines and validated the mechanisms in an animal model and patients respectively.
https://stemcellsjournals.onlinelibrary.wiley.com/doi/10.1002/stem.2245
https://link.springer.com/article/10.1007%2Fs00109-016-1455-7
I agree with you. I have bought a couple of biotechs recently (to average down) and I expect another big rally next year like we had his year. IKT is one. Another is CUBT.
They have been clobbered, but not because of any negative news. Just a lack of substantial news.
Just think if a short term gain is what tempts someone now, you can decide in January whether or not to hold for longer.
Thanks for sharing that, 3F.
There is a whole new world out there for companies that up list. More serious investors, better options for financing, potential for professional analyst coverage, more serious media coverage and much better partnership potential.
Getting past the tax loss selling is the obvious hurdle right now. But if you sell now to book that loss, you cannot buy back in for 30 days to keep that loss.
The risk is whether or not the tax loss is worth more than having to buy back in at potentially higher prices in January
Would you agree, 3F?
Small biotechs are in a bear market with this tax loss selling. If you buy wisely, you can do great buying now and selling in January
Apparently there are two publications coming out with data related to CUBT, according to Dr. Bahrti post on Linked In. Stocktwits had a screen shot of replies.
Bet that does not happen at these prices. Between tax loss selling and no real news, CUBT becomes an obvious tax loss choice.
If the company surprised the market with good news, this would reverse pretty quickly. Right now, it takes cajones to accumulate down here.
Thirty days from now, we will be in a New Year and this tax loss selling will be over with. Question here would be--is CUBT higher than the current $.06 or lower? And is it worth buying in if you think it would be higher?
It would help if the company had real news--but you cannot make UP news. They would call that "fake" news.
Better to be professional and act professionally and communicate professionally rather than stoop to bogus efforts.
IND filing, funding, another trial milestone etc. is what would help during the next two weeks.
SOMEONE is buying in down here. There is always a buyer when there is a seller.
Remember Pearl Harbor.
Cheap prices are attracting buyers for a change. If the company has some real news soon, we could see a trend reversal.
Know it has been difficult recently, but this may be a "Blood in the Street" time.
Well said. Biotechs take time. Clinical trials. Fundraising.
Not being promotional in the media just to placate investors who want to see Tweets from the CEO.
A legit biotech has to LOOK legit to attract partners, Advisory Board members etc.
Buying now will probably look smart in January when tax loss selling is over.
Have you ever bought a stock in Nov and Dec that had been MUCH higher earlier in the year just to take advantage of the January Effect?
There are traders that do that every year--But a beat up stock down because of tax loss selling (not negative fundamental news) and sell in January when tax loss harvesting is over.
Usually the companies help things along with news, discretionary updates, interviews, blog posts etc. (assuming there is something to say).
We can get very insular her and lose perspective.
Someone is happy today--the guy who bought at .046.
Always darkest...before the dawn.
Biotechs do better after the first of the year
Not too long before the up listing happens
We know it must be tax loss selling. Kudos to those who have held off in buying more until today.
Anyone getting shares today will probably see a 100 to 150 percent gain by Jan. Tax selling WILL
End by end of Dec.
Wish the company was not so quiet.
Gl
Thanks for that info.
I missed that. If they could advance the vaccine program to interest a Big Pharma in the COVID vaccine business, it would be a game changer for CUBT and MABT. One would think that Catherine Sohn is involved in this--with her business relationships at GSK.
If MABT felt comfortable to mention in a presentation that they have conducted some trials or lab work that showed a 5x increase in antibody titer vs. the vaccine alone, that development, IMHO, should be FAST TRACKED.
The time is now-- a pandemic that is not going away BECAUSE the antibody titer does NOT stay elevated for long after "vaccination".
CNBC had an analyst that had a $12 Target price. Lol
Where is this 5 x antibodies COVID vaccine reference?
Tia
Did you notice that they have a new Securities Counsel? Silvestre Law Group out of California.
Thanks for the tweet link. Very disturbing. I jumped at the "Mild" description too.
Trying to be too hopeful.
Toxic financing rarely works out for shareholders.
IF the company just need a short term shot of capital to get over a near term hurdle, the LPC funding might have made sense. But when you have to back again and again to dilute for more cash, the only ones benefiting (besides LPC) are the insiders on the payroll.
Sad.
3F? Any thoughts on when UNQL will complet thie nex move?
Do you think they will wait until January?
Thanks in advance for your reply.
You are right. MABT is Mid Atlantic BioTherapeutics, a partner with CUBT.
The CEO put up a message on his LinkedIn page
Mid-Atlantic BioTherapeutics (MABT)
424 followers
1. We need vaccines that can be delivered cheaply and effectively everywhere on earth to developed and undeveloped nations; if everyone isn’t vaccinated, we aren’t protected.
2. We need to make better vaccines for special populations, such as those with kidney failure, who are poorly responsive to the current vaccines.
3. We need to make better vaccines that will protect against the current and even future viral variants.
In collaboration with our partner, Curative Biotech, we continue to advance our COVID-19 vaccine that contains our proprietary IMT504 adjuvant.
https://www.linkedin.com/feed/update/urn:li:activity:6870774985783345152/
From a previous PR:
Curative Biotech and Mid-Atlantic BioTherapeutics have agreed to develop a next generation COVID-19 vaccine targeted to meet the needs of this vulnerable population. A consequence of kidney failure in general is the loss of a robust immunologic response to infections, including COVID-19. This means that kidney failure patients may get a more severe version of COVID-19 that could lead to a greater chance of hospitalization or even death.
Dr. David Horn, CEO of Mid-Atlantic BioTherapeutics, added: “It is well known that kidney transplant recipients have impaired responses to mRNA COVID-19 vaccines. Recent data from France reveals that, even after 4 vaccine shots, many kidney transplant recipients have poor responses. In addition, kidney failure patients on dialysis do not initially respond as well to current vaccines and rapidly lose measurable antibodies when compared to the general population.”
As previously announced, Curative Biotech has acquired the worldwide rights for the development of IMT504 to treat symptomatic rabies. Curative Biotech and MABT are already working together to develop IMT504 to treat patients whose disease has advanced to a stage where the virus has migrated to the brain, causing lethal rabies encephalitis. There are currently no treatment options for these patients.
IMT504 has already been granted orphan drug designation in the US for the treatment of rabies, which may provide significant benefits including tax credits, market exclusivity and the waiver of certain FDA fees. Rabies is one of only a limited number of diseases which qualify for the FDA Tropical Disease Priority Review Voucher (PRV) Program that is granted to sponsors of approved tropical disease product applications that meet certain criteria. Once the sponsor obtains a PRV, the voucher can be used to obtain priority review designation for a subsequent application that does not itself qualify for priority review as described in the guidance, and it can be sold to another party.
I bet Omnicrom is not going to be as bad as the Delta variant. Symptoms appear to be mild so far. But the vaccine marketplace is going to continue to expand in research etc.--including with small companies--to stay ahead of COVID going forward.
Once traders see that their delay in buying is costing them, meaning missing a lower price, UNQL will advance. A higher listing is going to change their future, imo.
Encouraging article here.
Dr. Horn, CEO of MABT, had a message on his LinkedIn page about their vaccine program with CUBT. Looks like it was posted on Friday.
On a separate note, it appears that we are seeing who has been selling here. No one would hold if they believed what they type.
End of the year update from the company would be welcome. Maybe in the CEO blog. And giving us an idea on the IND.
Youtube interview with Mr. Garr would be good too. He is impressive in that he is not over promotional. Just the facts. Very deliberate.
Headed to the airport. Wish me luck. Wearing a mask for three hours is not my idea of a holiday. But family is family.
Time will tell. You never know how much information is going to be required. And how long that will take.
It has been a long year.
NIO is in the Buy List before the end of Dec
Agreed,iRobot. All the behind the scenes progress and the PR says to me that there is preparation going on for more investor attention. Getting their ducks in line.
In the meantime, taking a tax loss is the rule of the day. Buyers just slowly pick off these cheap shares.
Picked up 25 k more today. Being patient is giving me a better price with this low volume.
Last few days to book a loss AND be able to buy back in BEFORE the end of the year. These beaten down stocks can really fit in January when tax loss selling ends.
But it is very risky if the company has good news that surprises before end of December
New variant of COVID has weirdly put more life into companies still working on a vaccine. Or a vaccine enhancer.
Sad that this pandemic continues. But it just might be a smaller biotech that no one know about who may get to the better vaccine, or therapy
Tough market for biotechs right now. Nothing really exiting the investors unless there are great results from a clinical trial.
PCAOB audit is a big deal when you are on these lower exchanges, imo.
Companies usually do not go through the expense or effort to become fully reporting with PCAOB unless there is a long term plan. In this case, it has to be for a future up listing. imo
https://www.pcaobus.org/resources/information-for-investors
If a company is OK with staying on these lower exchanges, they do not do PCAOB audits. Costs money.
Good to see all the posts on Stocktwits.com under "CUBT". The more, the merrier.
LOL-- I have one the same thing for a ton of times. Waiting for the perfect price and missing a great move to same .10 or so.
But then when you DO pay up--you find out that you could have bought the stock lower.